The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins
Open accessAbstract
Missense mutations in two related genes, termed presenilin 1 (PS1) and presenilin 2 (PS2), cause dementia in a subset of early-onset familial Alzheimer's disease (FAD) pedigrees. In a variety of experimental in vitro and in vivo settings, FAD-linked presenilin variants influence the processing of the amyloid precursor protein (APP), leading to elevated levels of the highly fibrillogenic Abeta1-42 peptides that are preferentially deposited in the brains of Alzheimer Disease (AD) patients. In this report, we demonstrate that transgenic animals that coexpress a FAD-linked human PS1 variant (A246E) and a chimeric mouse/human APP harboring mutations linked to Swedish FAD kindreds (APP swe) develop numerous amyloid deposits much earlier than age-matched mice expressing APP swe and wild-type Hu PS1 or APP swe alone. These results provide evidence for the view that one pathogenic mechanism by which FAD-linked mutant PS1 causes AD is to accelerate the rate of beta-amyloid deposition in brain.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, APP mice develop dystrophic neurites immediately around plaques (50), suggesting that this neuronal pathology is independent of cell death.”
From Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice (2013) · cites this paper as [50]
In the citing paper
“However, such studies have not definitively identified which Aβ species are responsible for seeding amyloid deposition in either the parenchyma or vasculature.”
From Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice (2005) · cites this paper as Borchelt et al., 1997
In the citing paper
“Increasing relative Aβ42 levels lowers the age when deposition first occurs, increases the amount of diffuse Aβ, and promotes parenchymal versus cerebrovascular deposition.”
From Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice (2005) · cites this paper as Borchelt et al., 1997
In the citing paper
“These genetic findings led to several transgenic mouse models that successfully recapitulated Aβ plaque formation, increasing support for the hypothesis (Table 1) [23–29].”
From Systems-based proteomics to resolve the biology of Alzheimer’s disease beyond amyloid and tau (2021) · cites this paper as [24]
Citations
Cites
1 retracted
Familial Alzheimer's disease associated with S182 codon 286 mutation
Chapman, J., Asherov, A., Wang, N., Treves, T. A., Korczyn, A. D., & Goldfarb, L. G. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91723-3 · Cited by 25
RetractedMcKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Self-citationGoate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Candidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Self-citationRogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Research works printed but not linked: 2
- Barelli, 1997, Characterization of new polyclonal antibodies specific for 40 and 42 amino acid-long amyloid β peptides, Mol. Med, in press
- Kim, 1990, Detection and quantitation of amyloid β-peptide with 2 monoclonal antibodies, Neurosci. Res. Commun, 7, 113
Cited by
Sorted by citations
Items 701–800 of 1,000
Aβ Deposition Does Not Cause the Aggregation of Endogenous Tau in Transgenic Mice
Xu, G. M., Gonzales, V., & Borchelt, D. (2002) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200207000-00011 · Cited by 19
Self-citationRecent work on Alzheimer's disease transgenics
Duff, K. (1998) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(98)80132-8 · Cited by 19
A Perspective on the Potential Involvement of Impaired Proteostasis in Neuropsychiatric Disorders
Hui, K. K., Endo, R., Sawa, A., & Tanaka, M. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.09.001 · Cited by 18
Jung, Y., Lee, Y., Choi, D., & Hong, J. T. (2014) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2014.030 · Cited by 18
Kim, J. A., Yun, H., Jin, P., Lee, H. P., Han, J. Y., Udumula, V., Moon, D. C., Han, S., Oh, K. W., Ham, Y. W., et al. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.06.032 · Cited by 18
The GSM BPN-15606 as a Potential Candidate for Preventative Therapy in Alzheimer’s Disease
Prikhodko, O., Rynearson, K. D., Sekhon, T., Mante, M., Nguyen, P. D., Rissman, R. A., Tanzi, R. E., & Wagner, S. L. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190442 · Cited by 18
Krishna‐K, K., Baby, N., Raghuraman, R., Navakkode, S., Behnisch, T., & Sajikumar, S. (2020) · The FASEB Journal · doi:10.1096/fj.201902844rr · Cited by 18
Alzheimer's disease and related dementias
Hardy, J. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139087711.003 · Cited by 18
Lazo, N. D., Maji, S. K., Fradinger, E. A., Bitan, G., & Teplow, D. B. (2005) · Wiley eBooks · doi:10.1002/9783527619344.ch17 · Cited by 18
Neurogenic effects of β-amyloid in the choroid plexus epithelial cells in Alzheimer’s disease
Bolós, M., Spuch, C., Ordóñez‐Gutiérrez, L., Wandosell, F. G., Ferrer, I., & Carro, E. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1300-x · Cited by 18
Regional brain evaluation of acetylcholinesterase activity in PS1/A246E transgenic mice
Jazi, R., Lalonde, R., Qian, S., & Strazielle, C. (2008) · Neuroscience Research · doi:10.1016/j.neures.2008.11.002 · Cited by 18
de Diego, A. M. G., Lorrio, S., Calvo‐Gallardo, E., & de Diego, A. M. G. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.10.082 · Cited by 18
Sinnige, T., Stroobants, K., Dobson, C. M., & Vendruscolo, M. (2020) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583520000025 · Cited by 18
Ess, P. J. V., Pedersen, W. A., Culmsee, C., Mattson, M. P., & Blouin, R. A. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2001.00724.x · Cited by 18
Mouse models as a tool for understanding neurodegenerative diseases
Ahmad‐Annuar, A., Tabrizi, S. J., & Fisher, E. (2003) · Current Opinion in Neurology · doi:10.1097/01.wco.0000084221.82329.29 · Cited by 18
Mănescu, M. D., Cătălin, B., Bâldea, I., Mateescu, V. O., Roşu, G. C., Boboc, I. K. Ş., Istrate-Ofiţeru, A.-M., Liliac, I. M., Streba, C. T., Kumar‐Singh, S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70164 · Cited by 17
Crowe, K. E., Zygmunt, D. A., Heller, K., Rodino-Klapac, L., Noguchi, S., Nishino, I., & Martin, P. T. (2021) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-200575 · Cited by 17
Dikranian, K. T., Kim, J., Stewart, F. R., Levy, M. A., & Holtzman, D. M. (2012) · Europe PMC (PubMed Central) · Cited by 17
Kedikian, G., Heredia, F., Rozés‐Salvador, V., Raimunda, D., Isoardi, N. A., Heredia, L., & Lorenzo, A. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22347 · Cited by 17
Woolley, M. L., & Ballard, T. M. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.02.007 · Cited by 17
Neurotransmitters and Energy Metabolites in Amyloid-Bearing APPSWE×PSEN1dE9 Mouse Brain
Hartmann, J., Kiewert, C., & Klein, J. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.161091 · Cited by 17
Presenilin-1 deficiency impairs glutamate-evoked intracellular calcium responses in neurons
Yang, Y., & Cook, D. G. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2003.11.029 · Cited by 17
Wang, J., Li, N., Ma, J., Gu, Z., Yu, L., Fu, X., Liu, X., & Wang, J. (2016) · Brain Research · doi:10.1016/j.brainres.2016.01.028 · Cited by 16
Animal Research for Alzheimer Disease: Failures of Science and Ethics
Pippin, J. J., Cavanaugh, S. E., & Pistollato, F. (2019) · BRILL eBooks · doi:10.1163/9789004391192_021 · Cited by 16
Time- and Sex-Dependent Effects of Fingolimod Treatment in a Mouse Model of Alzheimer’s Disease
Bascuñana, P., Brackhan, M., Möhle, L., Wu, J., Brüning, T., Eiriz, I., Jansone, B., & Pahnke, J. (2023) · Biomolecules · doi:10.3390/biom13020331 · Cited by 16
Tolédano, A., Álvarez, M. I., López-Rodríguez, A. B., Toledano‐Díaz, A., & Fernández, C. I. (2011) · Neurología · doi:10.1016/j.nrl.2011.05.008 · Cited by 16
Hamezah, H. S., Durani, L. W., Yanagisawa, D., Ibrahim, N. F., Aizat, W. M., Makpol, S., Ngah, W. Z. W., Damanhuri, H. A., & Tooyama, I. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181171 · Cited by 16
Alzheimer's disease, amyotrophic lateral sclerosis, and transgenic mice
Bajaj, N. P. S., Irving, N. G., Leigh, P. N., & MILLER, C. C. J. (1998) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.6.711 · Cited by 16
Capsoni, S., Marinelli, S., Ceci, M., Vignone, D., Amato, G., Malerba, F., Paoletti, F., Meli, G., Viegi, A., Pavone, F., et al. (2012) · PLoS ONE · doi:10.1371/annotation/97b6c799-1ebc-4e7b-8f86-47c1130dc00e · Cited by 16
Gao, B.-B., Long, Z., Zhao, L., & He, G. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110308 · Cited by 15
Kishimoto, Y., & Kirino, Y. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.01.025 · Cited by 15
Zhang, C., Kuo, C., Chiu, A. W. L., & Feng, J. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120028 · Cited by 15
Kukharsky, M. S., Овчинников, Р. К., & Бачурин, С. О. (2015) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20151156103-114 · Cited by 15
Unger, T. L., Korade, Ž., Lazarov, O., Terrano, D. T., Schor, N. F., Sisodia, S. S., & Mirnics, K. (2005) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200512000-00003 · Cited by 15
Self-citationLink, C. D., Brown, M. K., Luo, Y., & Wu, Y. (2008) · Frontiers in neuroscience · doi:10.1201/noe1420052343.ch16 · Cited by 15
Intracerebroventricular passive immunization in transgenic mouse models of Alzheimer’s disease
Chauhan, N. B., & Siegel, G. J. (2004) · Expert Review of Vaccines · doi:10.1586/14760584.3.6.717 · Cited by 15
Fishman, C. E., Cummins, D. J., Bales, K. R., DeLong, C. A., Esterman, M. A., Hanson, J. C., White, S. L., Paul, S. M., & Jordan, W. H. (2001) · Journal of Neuroscience Methods · doi:10.1016/s0165-0270(01)00381-8 · Cited by 15
Sinnige, T., Stroobants, K., Dobson, C. M., & Vendruscolo, M. (2020) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583520000104 · Cited by 15
Mutant presenilin-1 deregulated peripheral immunity exacerbates Alzheimer-like pathology
Zhu, Y., Obregon, D. F., Hou, H., Giunta, B. N., Ehrhart, J. C., Fernandez, F., Mori, T., Nikolic, W. V., Zhao, Y., Morgan, D., et al. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00962.x · Cited by 14
Critical thinking of Alzheimer’s transgenic mouse model: current research and future perspective
Li, X., Quan, M., Wei, Y., Wang, W., Xu, L., Wang, Q., & Jia, J. (2023) · Science China Life Sciences · doi:10.1007/s11427-022-2357-x · Cited by 14
Amygdala in Alzheimer's Disease
Knafo, S. (2012) · InTech eBooks · doi:10.5772/52804 · Cited by 14
Age‐related modulation of γ‐secretase activity in non‐human primate brains
Nishimura, M., Nakamura, S., Kimura, N., Liu, L., Suzuki, T., & Tooyama, I. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07884.x · Cited by 14
Hirsch‐Reinshagen, V., Chan, J. Y., Wilkinson, A., Tanaka, T., Fan, J., Ou, G., Maia, L. F., Singaraja, R. R., Hayden, M. R., & Wellington, C. L. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m600543-jlr200 · Cited by 14
Prospects for Early Detection of Alzheimers Disease from Serial MR Images in Transgenic Mouse Models
Muskulus, M., Scheenstra, A. E. H., Braakman, N., Dijkstra, J., Lunel, S. M. V., Alia, A., de Groot, H. J. M., & Reiber, J. H. C. (2009) · Current Alzheimer Research · doi:10.2174/156720509790147089 · Cited by 14
Transcriptional regulation of the presenilin-1 gene controls gamma-secretase activity
Das, H. K. (2010) · Frontiers in Bioscience-Elite · doi:10.2741/e61 · Cited by 14
Miettinen, R. A., Riedel, A., Kalesnykas, G., Kettunen, H.-P., Puoliväli, J. T., Soininen, H. S., & Arendt, T. (2005) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2005.06.003 · Cited by 14
Chapter 4. Secretase inhibitors as therapeutics for Alzheimer's disease
Olson, R. E., & Thompson, L. A. (2000) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(00)35005-9 · Cited by 14
Wong, P. C., Cai, H., Borcheit, D. R., & Price, D. L. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:233 · Cited by 14
Self-citationFilali, M., & Lalonde, R. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.12.018 · Cited by 13
Retinal Changes in Transgenic Mouse Models of Alzheimer’s Disease
Guo, L., Ravindran, N., Shamsher, E., Hill, D., & Cordeiro, M. F. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666210414113634 · Cited by 13
Reduced anxiety in the mice expressing mutant (N141I) presenilin 2
Yuk, D. Y., Lee, Y. K., Nam, S.-Y., Yun, Y. W., Hwang, D. Y., Choi, D. Y., Oh, K. W., & Hong, J. T. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21861 · Cited by 13
Wang, J., Ikonen, S., Gurevicius, K., Groen, T. V., & Tanila, H. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00714-5 · Cited by 13
The Biochemistry of Alzheimer??s Disease
Stege, G. J. J., & Bosman, G. J. C. G. M. (1999) · Drugs & Aging · doi:10.2165/00002512-199914060-00004 · Cited by 13
Hsiao, K. (1998) · Progress in brain research · doi:10.1016/s0079-6123(08)64026-1 · Cited by 13
The function of presenilin-1 in amyloid β-peptide generation and brain development
Säftig, P., Hartmann, D., & Strooper, B. D. (1999) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s004060050099 · Cited by 13
Volonté, C., Hu, G., Shaw, C. A., Claudio, V. J., dos Santos, J. A., Vaz, S. H., Sebastião, A. M., Balcar, V. J., Mozley, P. D., Verde, F., et al. (2026) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2026.1004136 · Cited by 12
Fingolimod mitigates synaptic deficits and psychosis‐like behavior in APP/PSEN1 mice
Krivinko, J. M., Erickson, S. L., MacDonald, M. L., Garver, M. E., & Sweet, R. A. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12324 · Cited by 12
Sato, N., Shinohara, M., Rakugi, H., & Morishita, R. (2012) · Neurodegenerative Diseases · doi:10.1159/000334534 · Cited by 12
Detecting bioactive amyloid β peptide species in Alzheimer's disease
Liu, Y., Dargusch, R., Banh, C., Miller, C. A., & Schubert, D. A. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02751.x · Cited by 12
Modulators of Amyloid β-Protein (Aβ) Self-Assembly
Rahimi, F., Li, H. J., Sinha, S., & Bitan, G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00006-x · Cited by 12
Altered exocytosis in chromaffin cells from mouse models of neurodegenerative diseases
de Diego, A. M. G., & Garcı́a, A. G. (2018) · Acta Physiologica · doi:10.1111/apha.13090 · Cited by 12
The study of behavioral dysfunctions
van der Staay, F. J. (2000) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 12
Qin, K., Zhao, L., Gregory, C., Solanki, A., & Mastrianni, J. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-44317-w · Cited by 12
Chapter 23 Alzheimer's disease: Identification of genes and genetic risk factors
Broeckhoven, C. V. (1998) · Progress in brain research · doi:10.1016/s0079-6123(08)64024-8 · Cited by 12
Amyloid β-Peptide: Biphasic Dose Responses
Calabrese, E. J. (2001) · Critical Reviews in Toxicology · doi:10.1080/20014091111857 · Cited by 12
Establishment of experimental models for Alzheimer's disease research
Li, Y. (2013) · International Journal of Neuroscience · doi:10.3109/00207454.2013.804821 · Cited by 11
Xing, S., Shen, D., Chen, C., Wu, B., & Chi, H. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4732 · Cited by 11
Li, N., Hu, P., Xu, T., Chen, H., Chen, X., Hu, J., Yang, X., Shi, L., Luo, J., & Xu, J. (2017) · Current Alzheimer Research · doi:10.2174/1567205014666170719165745 · Cited by 11
Rejc, L., Gómez‐Vallejo, V., Ríos, X., Cossío, U., Baz, Z., Mujica, E., Gião, T., Cotrina, E. Y., Jiménez‐Barbero, J., Quintana, J. R., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200570 · Cited by 11
Locus Coeruleus and Noradrenergic Pharmacology in Neurodegenerative Disease
Matt, R. A., Martin, R. S., Evans, A. K., Gever, J. R., Vargas, G. A., Shamloo, M., & Ford, A. P. D. W. (2023) · Handbook of experimental pharmacology · doi:10.1007/164_2023_677 · Cited by 11
Protease Inhibitors and their Involvement in Neurological Disorders
Tizón, B., & Levy, E. (2007) · Springer eBooks · doi:10.1007/978-0-387-30379-6_20 · Cited by 11
Neuroprotective Strategies in Alzheimer’s Disease
Behl, C. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0123-7_18 · Cited by 11
Saiyisan, A., Zeng, S., Zhang, H., Wang, Z., Wang, J., Cai, P., & Huang, J. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-01246 · Cited by 10
Beyond the brain: early autonomic dysfunction in Alzheimer’s disease
Nanclares, C., Colmena, I., Muñoz-Montero, A., Baraibar, A. M., de Pascual, R., Wojnicz, A., Ruíz‐Nuño, A., Garcı́a, A. G., Gironda-Martínez, A., & Gandı́a, L. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02042-8 · Cited by 10
Navakkode, S., & Kennedy, B. K. (2025) · Aging Cell · doi:10.1111/acel.70235 · Cited by 10
Tomita, T. (2016) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2016.10.033 · Cited by 10
Lopes, C. R., Silva, J. S., Santos, J., Rodrigues, M. S., Madeira, D., Oliveira, A., Moreira-de-Sá, A., Lourenço, V. S., Gonçalves, F. Q., Silva, H. B. L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24086968 · Cited by 10
Sha, S., Chaigneau, T., & Krantic, S. M. (2023) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2023.04.005 · Cited by 10
Wang, C.-M., deVries, S., Camboni, M., Glass, M., & Martin, P. T. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.05.013 · Cited by 10
The possible mechanisms of Aβ(1-40)- or Aβ(1-42)-induced cell death and their rescue factors
NAGAI, Y., OGASAWARA, A., & Heese, K. (2004) · Folia Pharmacologica Japonica · doi:10.1254/fpj.124.135 · Cited by 10
Deguil, J., Ravasi, L., Auffret, A., Babiloni, C., Bartrés‐Faz, D., Bragulat, V., Cassé‐Perrot, C., Colavito, V., Ezquerro, M. T. H., Lamberty, Y., et al. (2013) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2013.03.003 · Cited by 10
Cognitive rejuvenation through partial reprogramming of engram cells
Berdugo‐Vega, G., Sierra, C., Astori, S., Calati, V., Orsat, J., Scoglio, M. J., Sandi, C., & Gräff, J. (2026) · Neuron · doi:10.1016/j.neuron.2025.11.028 · Cited by 9
Camboni, M., Wang, C.-M., Miranda, C. J., Yoon, J. H., Xu, R., Zygmunt, D. A., Kaspar, B. K., & Martin, P. T. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.09.001 · Cited by 9
Fluoro-Jade: New fluorescent marker of Rosenthal fibers
Tanaka, K. F., Ochi, N., Hayashi, T., Ikeda, E., & Ikenaka, K. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.08.014 · Cited by 9
Krivinko, J. M., Erickson, S. L., Abrahamson, E. E., Wills, Z. P., Ikonomović, M. D., Penzes, P., & Sweet, R. A. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.02.006 · Cited by 9
Adibi, H., Mehrabi, M., Amiri, K., Balalaie, S., & Khodarahmi, R. (2019) · Journal of the Iranian Chemical Society · doi:10.1007/s13738-019-01776-2 · Cited by 9
Soto, P. L., Young, M. E., DiMarco, G. M., George, B. E., Melnikova, T., Savonenko, A. V., & Harris, B. N. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.03.010 · Cited by 9
Biomarker identification in neurologic diseases: improving diagnostics and therapeutics
Coon, K. D., Dunckley, T. L., & Stephan, D. A. (2004) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.4.3.361 · Cited by 9
Neurobiology of Alzheimer’s Disease
Wong, P. C., Savonenko, A. V., Li, T., & Price, D. L. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-374947-5.00046-8 · Cited by 9
Self-citationPotential application of RNAi for understanding and therapy of neurodegenerative diseases
Elena, I. S. (2009) · Frontiers in bioscience · doi:10.2741/3245 · Cited by 9
Recent advances in transgenic model development for Alzheimer's disease
Sommer, B. (1998) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.7.12.2017 · Cited by 9
Li, M., Yu, Q., Anayyat, U., Yang, H., Wei, Y., & Wang, X. (2024) · GeroScience · doi:10.1007/s11357-024-01223-y · Cited by 8
The Fundamental Neurobiological Mechanism of Oxidative Stress-Related 4E-BP2 Protein Deamidation
Joseph, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212268 · Cited by 8
Mini-review: Retarding aging in murine genetic models of neurodegeneration
Albin, R. L., & Miller, R. A. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.10.014 · Cited by 8
Savonenko, A. V., Wong, P. C., & Li, T. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00022-8 · Cited by 8
Yang, Y.-H., Hsieh, S., Chang, H., Sung, J.-L., Chuu, C., Yen, C., & Hour, T. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220307 · Cited by 8
Quantitative analysis of the capillary network of aged APPswe/PS1dE9 transgenic mice
Nikolajsen, G. N., Kotynski, K. A., Jensen, M. S., & West, M. J. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.08.004 · Cited by 8
Advances in genetic models of Parkinson's disease
Lee, M. K., & Price, D. L. (2001) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(01)00024-x · Cited by 8
Self-citationLeVine, H., & Walker, L. C. (2006) · Elsevier eBooks · doi:10.1016/b978-012369391-4/50012-6 · Cited by 8
Metadata
- Authors
- Borchelt, D. R., Ratovitski, T., van Lare, J., Lee, M. K., Gonzales, V., Jenkins, N. A., Copeland, N. G., Price, D. L., & Sisodia, S. S.
- Affiliations
- Johns Hopkins University (US)
- Frederick National Laboratory for Cancer Research (US)
- Corresponding author
- Borchelt, David R
- Venue
- Neuron
- Publisher
- Elsevier BV
- Published
- 1997-10
- Volume
- 19
- Issue
- 4
- Pages
- 939-945
- ISSN
- 0896-6273 (ISSN-L)
- OpenAlex
- W2062214806
- Cited by
- 1,023
- References
- 52
- Citations by year
- 2026: 9 · 2025: 13 · 2024: 16 · 2023: 17 · 2022: 18 · 2021: 36 · 2020: 35 · 2019: 25 · 2018: 30 · 2017: 38 · 2016: 29 · 2015: 38 · 2014: 33 · 2013: 44 · 2012: 46
- FWCI
- 17.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Neuron (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (AG 14248, P50AG005146, P01AG014248, AG 05146)
- National Institute of Neurological Disorders and Stroke (NS-20471)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- presenilin 1, presenilin 2, amyloid precursor protein, familial Alzheimer's disease, amyloid-beta deposition, transgenic mice, amyloid-beta 42, amyloidosis, Alzheimer's disease pathogenesis
- MeSH terms
- Aging, Alzheimer Disease, Amyloid, Animals, Brain, Family, Humans, Membrane Proteins, Mice, Transgenic, Pedigree, Recombinant Fusion Proteins, Sweden, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Mice, Presenilin-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
